Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 14/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.43 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13401138 | 0.86 | CTSL (0.49) | CTSLCTSKCTSSCTSBCTSC | |
| SCHEMBL21413355 | 0.78 | RXFP1 (0.45) | CTSLCTSKCTSSCTSBCTSC | |
| SCHEMBL2155600 | 0.77 | CTSL (0.46) | CTSLCTSKCTSSCTSBCTSC | |
| SCHEMBL8218554 | 0.75 | CTSL (0.54) | CTSLCTSKCTSSCTSBCTSC | |
| SCHEMBL4675931 | 0.75 | CTSL (0.54) | CTSLCTSKCTSSCTSBCTSC | |
| SCHEMBL24848504 | 0.74 | CTSL (0.43) | CTSLCTSKCTSSCTSBCTSC | |
| SCHEMBL18910071 | 0.74 | CTSC (0.53) | CTSLCTSKCTSSCTSBCTSC | |
| Hydrochloric Acid SCHEMBL23673462 | 0.74 | CTSL (0.53) | CTSLCTSKCTSSCTSBCTSC | |
| SCHEMBL23694015 | 0.74 | CTSL (0.64) | CTSLCTSKCTSSCTSB | |
| Hydrochloric Acid SCHEMBL23673461 | 0.74 | CTSL (0.53) | CTSLCTSKCTSSCTSBCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2597089-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | CTSL 4605/4885CTSK 3601/4885CTSS 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.